7 results about "Corneal limbus" patented technology

A method and device are disclosed for determining the position of a flap incision on a cornea and the position of the hinge associated with the flap. The method comprises the steps of: capturing an image of an eye, including at least the pupil and the limbus; determining a region including the outer circumference of the flap incision; determining the position of the flap incision; determining a straight region including the hinge; and determining the position of the hinge.

The present disclosure relates to intraocular implants for treating a condition of the eye, wherein the implant is configured to deliver a drug to the eye. The present disclosure also relates to methods of treating a condition of the eye by delivering a drug from intraocular implants to the posterior chamber (e.g., sulcus), iridocorneal angle, sclera, cornea, limbus, and vitreous.

The application discloses application of a norepinephrine inhibitor in preparation of a medicine for treating or relieving corneal limbal stem cell deficiency, and belongs to the technical field of medicines.The experiment proves that sympathetic nerves are excessively activated in a mouse model of corneal limbal stem cell deficiency, and the release of norepinephrine is increased, and the experiment proves that 6-hydroxydopamine hydrochloride can destroy sympathetic nerves to inhibit the release of norepinephrine, and a tyrosine hydroxylase inhibitor can inhibit the synthesis of norepinephrine, and both can further relieve the symptoms of corneal limbal stem cell deficiency.The norepinephrine inhibitor can improve the corneal limbal microenvironment, reduce corneal neovascularization, reduce corneal epithelialization, enhance corneal transparency and relieve corneal edema, and provides a new direction and a new way for the pathogenic mechanism and intervention target of corneal limbal stem cell deficiency, and has a wide application prospect.

Disclosed herein is a method of alleviating symptoms of ocular surface discomfort, the method comprising: topically applying a cold slurry adjacent to a corneal limbus of an eye of a patient, wherein the cold slurry comprises water and a freezing point depressant, wherein the topical application of the cold slurry is configured to cause a degree of numbing of a cornea of the eye for a period of time, and wherein an ocular sensation of the eye is restored following the period of time.

Disclosed herein is a method of alleviating symptoms of ocular surface discomfort, the method comprising: topically applying a cold slurry adjacent to a corneal limbus of an eye of a patient, wherein the cold slurry comprises water and a freezing point depressant, wherein the topical application of the cold slurry is configured to cause a degree of numbing of a cornea of the eye for a period of time, and wherein an ocular sensation of the eye is restored following the period of time.

The present invention relates to a sterile ophthalmic composition comprising castor oil and medium-chain triglycerides; to the use of said composition in medicine, in particular for the treatment and / or prevention of an ocular disease selected from the group consisting of dry eye, conjunctivitis, dermatitis, blepharitis, entropion, lax eye lid syndrome, thyroid eye disease, pterygium, conjunctival laxity, epithelial damage caused by preservatives, epithelial or anterior chamber damage caused by ocular surgery, corneal limbal cell deficiency, corneal ulceration caused by physical or chemical agents, keratitis, sub-scleritis and uveitis.

The invention provides application of vasoactive intestinal peptide VIP in preparation of a medicine for preventing and / or treating corneal epithelium lesion, and belongs to the technical field of biological medicine preparation. The invention discloses application of vasoactive intestinal peptide VIP in preparation of a medicine for preventing and / or treating corneal epithelium lesion. Researches show that diabetes can cause expression down-regulation of VIP and a receptor VIPR1 thereof in corneal limbus tissues, so that proliferation activity of corneal limbus stem cells of diabetic mice is reduced, and healing of corneal epithelium wounds is delayed. The exogenous supplement of VIP can effectively reverse the pathological change, significantly enhance the multiplication capacity of corneal limbal stem cells and accelerate the repair of corneal epithelium wounds; on the contrary, the VIPR1 receptor is knocked out, so that the proliferation activity of the corneal limbal stem cells is reduced, and the epithelium repair is delayed. Based on the results, the invention provides a new application of VIP in preparation of medicines for preventing and / or treating corneal epithelium lesions, and a new effective means is provided for repair treatment of the diseases.